6GDZ

exendin-4 based dual GLP-1/glucagon receptor agonist


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 20 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the least restraint violations 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.

Evers, A.Bossart, M.Pfeiffer-Marek, S.Elvert, R.Schreuder, H.Kurz, M.Stengelin, S.Lorenz, M.Herling, A.Konkar, A.Lukasczyk, U.Pfenninger, A.Lorenz, K.Haack, T.Kadereit, D.Wagner, M.

(2018) J Med Chem 61: 5580-5593

  • DOI: 10.1021/acs.jmedchem.8b00292
  • Primary Citation of Related Structures:  
    6GB1, 6GE2, 6GDZ

  • PubMed Abstract: 
  • Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor ...

    Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects.


    Organizational Affiliation

    Sanofi-Aventis Deutschland GmbH , R&D , Industriepark Höchst , D-65926 Frankfurt am Main , Germany.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Exendin-4A40Heloderma suspectumMutation(s): 1 
UniProt
Find proteins for P26349 (Heloderma suspectum)
Explore P26349 
Go to UniProtKB:  P26349
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EVT (Subject of Investigation/LOI)
Query on EVT

Download Ideal Coordinates CCD File 
B [auth A](2~{S})-2-[[(4~{S})-4-(hexadecanoylamino)-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]pentanedioic acid
C26 H46 N2 O8
JFNZOURGWMREOJ-SFTDATJTSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
AIB
Query on AIB
AL-PEPTIDE LINKINGC4 H9 N O2ALA
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 20 
  • Conformers Submitted: 10 
  • Selection Criteria: structures with the least restraint violations 
  • OLDERADO: 6GDZ Olderado

Structure Validation

View Full Validation Report




Entry History 

Deposition Data

  • Deposited Date: 2018-04-25 
  • Released Date: 2018-06-20 
  • Deposition Author(s): Evers, A., Kurz, M.

Revision History  (Full details and data files)

  • Version 1.0: 2018-06-20
    Type: Initial release
  • Version 1.1: 2018-07-25
    Changes: Data collection, Database references
  • Version 1.2: 2019-05-08
    Changes: Data collection